Core Insights - The company is presenting updates on two solid tumor programs at ESMO 2025, focusing on a TGF-beta receptor II by PD-1 bispecific and a KRAS G12D inhibitor [1] - The presentation includes insights from key team members regarding the biological rationale and future plans for these programs [2] Group 1 - The solid tumor update is being held in Berlin, with both in-person and online attendance [1] - The two programs discussed are the TGF-beta receptor II by PD-1 bispecific and the KRAS G12D inhibitor, with data presented at the event [1] - The agenda includes presentations from the Chief Scientific Officer, Head of Early Development, and Chief Medical Officer, focusing on the biology, data sets, and future plans for the programs [2]